Clinical Guides
Hirsutism
A clinically focused guide to unwanted terminal hair growth in an androgen-dependent pattern, its safe endocrine evaluation, patient-centred management and Indian practice limitations.
MedNext Academy | 12 min read
Hirsutism
A clinically focused guide to unwanted terminal hair growth in an androgen-dependent pattern, its safe endocrine evaluation, patient-centred management and Indian practice limitations.
Summary
Hirsutism means excessive terminal hair growth in a male-pattern distribution in a woman or girl, commonly on the upper lip, chin, chest, abdomen, back or thighs. It is distinct from hypertrichosis, which is generalised or non-androgen-dependent hair growth, and from a patient’s entirely valid cosmetic concern about normal hair distribution. The clinical aim is neither to impose a beauty standard nor to dismiss distress: establish the pattern, tempo, menstrual and reproductive context, medicines and signs of androgen excess, then choose care with the patient.
Polycystic ovary syndrome (PCOS) is a common cause of persistent hirsutism, but it must not become an automatic diagnosis. Rapid progression, new virilisation, onset after menopause, severe biochemical androgen excess, Cushingoid features, galactorrhoea, acromegalic change or an abdominal mass needs timely cause-directed assessment. A regular cycle and modest local hair growth make a serious endocrine disorder less likely, but do not override an atypical history or examination.
Hair change is slow. Treatment response is generally assessed after months, not days, because medicines affect new growth rather than instantly removing existing terminal hair. This draft is educational and has been reviewed by the MedNext Clinical Team; it does not diagnose PCOS, recommend a cosmetic outcome, replace pregnancy testing or prescribe hormonal or antiandrogen treatment without an Indian clinician, current formulary and reliable contraception where required.
How Common Is It?
The measured frequency of hirsutism varies with the definition, population, ethnicity, life stage, observer and the threshold used on a hair-score scale. The Endocrine Society notes that hair distribution differs by ethnicity and recommends that the clinician consider patient-important unwanted growth as well as a score. A single global percentage therefore cannot honestly be presented as the prevalence in India. Referral clinics are enriched for more severe or distressing presentations and cannot represent community burden.
Hirsutism may first be noticed around puberty, persist with PCOS, develop with medicines, or emerge later with ovarian or adrenal disorders. Its impact is not proportional to a score alone: facial hair, scarring from removal methods, stigma, anxiety, depression and the time or cost of hair removal can be substantial at lower measured scores. Conversely, a higher score does not identify the biochemical cause or need for treatment without history and examination.
Indian estimates depend on local sampling, hair-removal practices, cosmetic norms, availability of endocrine testing and use of PCOS definitions. The international PCOS guideline describes evidence for people with PCOS, not prevalence for all hirsutism. This source set provides no nationally representative Indian hirsutism survey. Services should document symptom burden, menstrual and metabolic context, diagnostic delay and access to treatment rather than borrow an unverified statistic.
Risk Factors
PCOS, family tendency, insulin resistance and obesity can be associated with hirsutism, but risk is not destiny and body size is not a diagnosis. Ask about puberty, menstrual regularity, fertility intention, weight trajectory, acne, scalp hair loss, voice change, increased muscle mass and clitoromegaly. Review glucocorticoids, androgens or anabolic agents, progestins, minoxidil, ciclosporin, phenytoin, valproate and any unlabelled supplement. A medicine can cause hypertrichosis rather than true androgen-pattern hirsutism, so distribution and timing remain important.
Adrenal or ovarian androgen-secreting tumours are uncommon but clinically important when onset is rapid or virilisation appears. Non-classic congenital adrenal hyperplasia, Cushing syndrome, hyperprolactinaemia, thyroid dysfunction, severe insulin resistance and acromegaly are considered when features support them. Menstrual irregularity or infertility increases the probability of ovulatory dysfunction but is not a substitute for exclusion of pregnancy and other causes.
In India, access to reliable assays, ultrasound, dermatology, endocrinology, contraception counselling and licensed laser services may vary. Ask about self-medication, cosmetic products, stigma, safety at home and whether pregnancy is possible before discussing therapy. These are access questions, not assumptions about a person’s culture or choices. Evidence from international endocrine and PCOS guidance must be reconciled with local laboratory reference ranges, medicine labels and specialist pathways.
Diagnosis
History
Ask when growth began, how fast it changed, sites affected, previous removal methods, menstrual pattern, fertility intention, pregnancy possibility, acne, alopecia, virilisation, weight and sleep change, bruising, weakness, headaches, visual symptoms, galactorrhoea and medication or supplement exposure. Determine whether hair is terminal and androgen-pattern or diffuse fine growth. A patient’s perceived distress and treatment goal matter even when a formal score is low. Record family pattern and relevant metabolic, endocrine and cancer history without treating any history as proof of cause.
Examination
Use respectful consent, privacy and a chaperone where wanted. Document blood pressure, BMI or waist only when clinically useful, acne, alopecia, acanthosis nigricans, bruising, striae, proximal weakness, thyroid signs, galactorrhoea where indicated and features of virilisation. A modified Ferriman-Gallwey assessment samples nine androgen-sensitive areas, but score interpretation varies by population and should never delay action for obvious rapid virilisation. Examine the abdomen or pelvis only for a specific clinical question and within competence.
Investigations
The Endocrine Society recommends total testosterone testing in women with an abnormal hirsutism score and testing reliable free testosterone when total testosterone is normal but moderate or severe hirsutism, progression or other hyperandrogenic features exist. Test 17-hydroxyprogesterone in those with a high likelihood of non-classic congenital adrenal hyperplasia. Pregnancy testing, prolactin, TSH, glucose or glycaemic assessment, lipids, cortisol testing, DHEAS, imaging and other tests are selected by phenotype. Do not use pelvic ultrasound alone to diagnose PCOS; use current diagnostic criteria and exclude mimics.
Differential Diagnosis
PCOS is a frequent cause, particularly with chronic ovulatory dysfunction and hyperandrogenic features, but diagnosis requires the current criteria and exclusion of alternative disorders. Idiopathic hirsutism is considered when cycles are regular, androgen testing and evaluation are normal and there is no other explanation; it is a diagnosis of exclusion, not a synonym for ‘nothing is wrong’. Familial or ethnic variation can coexist with genuine distress and a request for treatment.
Non-classic congenital adrenal hyperplasia, ovarian hyperthecosis, androgen-producing ovarian or adrenal tumours, Cushing syndrome, acromegaly, hyperprolactinaemia, thyroid disease and severe insulin-resistance syndromes have discriminating clinical or laboratory features. Rapidly progressive hair growth with deepened voice, clitoromegaly or marked muscle change is particularly concerning for severe androgen excess. Postmenopausal new-onset hirsutism needs a different threshold for specialist evaluation than stable pubertal-onset symptoms.
Hypertrichosis may be drug-related, nutritional, systemic or constitutional and is not confined to androgen-dependent sites. Acne alone, hair loss alone or obesity alone does not establish hirsutism or PCOS. Medication history can prevent unnecessary imaging. Conversely, a normal initial hormone value does not end assessment when the phenotype is rapidly changing; confirm assay quality, timing, medicine effects and whether specialist-directed repeat testing or imaging is needed.
Management
Start by agreeing what the person wants to change: diagnosis reassurance, slower new growth, treatment of menstrual symptoms, fertility planning, metabolic health, hair-removal support or distress reduction. Explain that shaving, trimming, waxing, depilatories, bleaching, threading, electrolysis and laser/light methods have different cost, irritation, pigment and effectiveness profiles. These choices do not worsen the biological cause. Skin irritation, folliculitis, scarring or pigment change needs dermatological advice rather than repeated traumatic removal.
For hirsutism with PCOS, the 2023 international guideline says a combined oral contraceptive pill can be recommended for reproductive-age adults for hirsutism and/or irregular cycles, subject to general contraindications and shared decision-making. The Endocrine Society suggests oral contraceptives as initial pharmacological therapy for most women not seeking fertility, and antiandrogen therapy only with adequate contraception because of fetal risk. If response is insufficient after a reasonable trial, combination treatment may be considered by an experienced prescriber. Do not use flutamide because of hepatotoxicity.
Lifestyle support can improve general health and may help PCOS-related metabolic risk, but should not be framed as a prerequisite for respect or care. Treat a tumour, CAH, Cushing syndrome, thyroid disorder or medicine trigger specifically. Provide follow-up after an agreed interval to review hair change, adverse effects, mood, blood pressure, pregnancy intention and adherence barriers. Screen for distress and offer mental-health support without implying that the symptom is imaginary.
Prescribing Information
Before hormonal treatment, establish pregnancy possibility, fertility intention, thromboembolism risk, smoking, migraine with aura, blood pressure, liver disease, breast cancer history, drug interactions and the current Indian product label. Combined oral contraceptives are not a generic ‘hair tablet’; selection follows contraception eligibility and patient preference. The 2023 PCOS guideline does not identify one specific progestin, estrogen dose or combination as universally superior for hirsutism. Prescribe a licensed preparation, explain missed-pill action and review blood pressure and adverse effects using local guidance.
Antiandrogens can improve hirsutism but may harm a male fetus, so reliable contraception and pregnancy counselling are essential if used. Spironolactone, finasteride and other agents have different monitoring, contraindications and off-label status; exact dose, baseline testing and follow-up must come from local policy and specialist prescribing. Do not give antiandrogen monotherapy to someone who could become pregnant without reliable contraception. Flutamide should not be used because the Endocrine Society recommends against it owing to hepatic toxicity.
Metformin is not a primary cosmetic hair-removal drug; in PCOS its role depends on metabolic indication and the broader plan. Topical eflornithine availability and licensing vary. Laser or photoepilation requires informed discussion about skin type, hair colour, pregnancy, scarring risk, service competence and expense. Check for interaction with teratogenic, hepatotoxic or potassium-altering medicines. The absence of a product in a public service should trigger shared alternatives or referral, not unsafe unregulated treatment.
When to Refer
Urgent endocrinology or gynaecology assessment is indicated for rapidly progressive hirsutism, virilisation, a suspected androgen-secreting tumour, new postmenopausal onset, a pelvic or abdominal mass, severe Cushingoid features, or concerning neurological or visual symptoms with galactorrhoea. An emergency pathway is needed if there is acute severe abdominal pain, haemodynamic instability or another non-hirsutism emergency. Do not delay referral solely to complete every outpatient assay when the tempo and examination are concerning.
Routine specialist input is appropriate for diagnostic uncertainty, markedly abnormal androgens, suspected non-classic CAH, persistent distress despite first-line care, complex PCOS, infertility, contraindication to hormonal therapy, significant metabolic disease, difficult medication adverse effects or an adolescent in whom normal pubertal change and PCOS are difficult to distinguish. Dermatology can guide hair-removal complications; psychology or psychiatry can support distress, body image, anxiety or depression.
A useful referral includes onset and progression, menstrual and pregnancy history, virilisation, medicines and supplements, examination and hair-score method if used, all laboratory values with units and reference ranges, imaging, fertility goals, prior therapies and response. Indian referral availability varies, so the sending clinician should identify a service able to interpret endocrine assays and arrange contraception or pregnancy-safe interim care. Referral does not excuse respectful symptom management while waiting.
Red Flags
Rapid onset or progression over months, deepening voice, clitoromegaly, rapidly increasing muscle mass, severe androgenic alopecia, markedly increased libido or new severe acne suggests significant androgen excess and warrants urgent specialist evaluation. New hirsutism after menopause, a palpable abdominal or pelvic mass, unexplained weight loss or persistent abdominal distension increases concern for ovarian or adrenal pathology. A hair score should not reassure against these changes.
Wide purple striae, easy bruising, proximal muscle weakness, new difficult hypertension or diabetes, facial plethora or recurrent infection raise concern for hypercortisolism when present together. Headache, visual-field symptoms and galactorrhoea suggest pituitary disease; severe acanthosis or abrupt metabolic deterioration may indicate severe insulin resistance. Amenorrhoea always requires pregnancy consideration before attributing it to PCOS.
Medication and supplement review is a safety assessment. Unlabelled hormonal, bodybuilding or ‘herbal’ products can contain androgenic or glucocorticoid substances. New symptoms after a medicine change should prompt verification of ingredients and a prescriber review rather than abrupt withdrawal of essential therapy. Tell patients to seek urgent care for acute pelvic pain, collapse, severe headache with visual change or pregnancy-related concern. Red flags alter investigation and referral thresholds; they do not independently identify a diagnosis.
Indian Clinical Context
This is an India-jurisdiction educational guide, but its hirsutism-specific evidence comes from international Endocrine Society and PCOS guidance. Those documents do not define Indian medicine licensing, assay availability, public-sector access, laser regulation or a national cosmetic standard. Local clinicians must use current Indian labels, contraception guidance, laboratory reference intervals and referral pathways. The NMC curriculum provides an educational framework, not a patient-specific endocrine protocol.
In practice, ask whether hormone tests can be performed by a reliable laboratory, whether the person can return for results, whether pregnancy testing and contraception are accessible, and whether hair removal has caused burns, scarring or pigment change. Discuss menstrual and sexual history confidentially and without assuming marital status, sexual activity, fertility goals or ability to pay. Teleconsultation photographs require explicit consent and secure handling; they are not a substitute for examining virilisation or a mass.
India-specific epidemiology and service-access evidence are not established by the sources used here. A facility without endocrine assays or imaging should recognise rapid virilisation and arrange early referral rather than falsely reassure. Conversely, limited access does not justify indiscriminate panels or unregulated antiandrogen use. Provide an interim explanation, safe hair-removal advice, pregnancy precautions and clear return signs in the patient’s preferred language.
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 is the authoritative framework for Indian undergraduate learning. Hirsutism integrates reproductive endocrinology, physiology, pathology, pharmacology, dermatology, general medicine, gynaecology, communication and ethics. Exact competency codes and phase allocation should be verified in the institution’s adopted NMC ledger rather than invented in this review candidate.
At knowledge level, learners should distinguish terminal androgen-pattern hair from hypertrichosis, explain ovarian and adrenal androgen physiology, list PCOS and dangerous secondary causes, and describe why pregnancy intention changes treatment safety. At reasoning level, they should elicit tempo, menstrual pattern, drug exposure and virilisation; use a focused, consent-based examination; select total testosterone and targeted tests; and explain why a score is an aid rather than a verdict. They should identify tumour, Cushing syndrome and pituitary warning patterns.
Under supervision, a learner can communicate non-stigmatisingly, obtain consent for sensitive questions and examination, document fertility wishes, counsel that antiandrogens require contraception, and arrange referral. Students should not independently diagnose PCOS from an ultrasound, prescribe contraceptives or antiandrogens, assess contraindications beyond competence, or rule out a tumour from one result. An OSCE should reward privacy, uncertainty, pregnancy safety and escalation rather than cosmetic judgement. This mapping does not confer independent practice or publication approval.
Key Exam Pearls for NEET PG
Hirsutism is terminal hair in androgen-dependent sites; hypertrichosis is excessive non-androgen-dependent hair growth. PCOS is common, but rapid progression or virilisation requires consideration of an androgen-secreting ovarian or adrenal tumour. High-yield virilisation clues are deep voice, clitoromegaly, marked muscle change and severe rapid alopecia. Always ask onset and tempo before choosing a broad endocrine panel.
The modified Ferriman-Gallwey score assesses nine areas, but interpretation is influenced by ethnicity and hair-removal practice. In women with an abnormal score, test total testosterone; if it is normal but hirsutism is moderate or severe, progressing, or accompanied by other hyperandrogenism, obtain reliable free testosterone. Test 17-hydroxyprogesterone when non-classic CAH likelihood is high. Do not diagnose PCOS from ovarian ultrasound alone.
For pharmacology, combined oral contraceptives are commonly first-line for those not seeking fertility after contraindication review. Antiandrogens need reliable contraception because of fetal risk; do not use flutamide because of hepatotoxicity. Hair-removal techniques address existing hair while drug treatment reduces new growth gradually. Examination answers must include pregnancy possibility, menstrual history, medication review and referral for rapid virilisation; do not give a universal dose without current local prescribing information. Clinical follow-up should also assess treatment-related adverse effects, wellbeing and new virilisation.
Frequently Asked Questions
Does facial hair automatically mean that a patient has polycystic ovary syndrome?
No. PCOS is common but hirsutism may be idiopathic, familial, medicine-related or caused by adrenal, ovarian, thyroid, pituitary or cortisol disorders. The diagnosis uses menstrual and reproductive history, examination, targeted testing and exclusion of important alternatives. Rapid change or virilisation requires specialist assessment rather than an automatic PCOS label.
Why is a pregnancy discussion necessary before antiandrogen treatment?
Antiandrogens may harm development of a male fetus. A clinician must establish pregnancy possibility, fertility intention and reliable contraception before prescribing them, and discuss what to do if a pregnancy is suspected. This is a safety requirement, not a judgement about sexual activity or reproductive choices.
Will hormonal treatment remove existing terminal hair immediately after it starts?
No. Hormonal and antiandrogen treatments reduce new androgen-dependent growth gradually, so benefit is usually judged after several months. Existing hair may still need shaving, trimming, waxing, laser, electrolysis or another chosen method. A sudden failure or rapid progression should prompt reassessment of diagnosis, adherence and safety rather than unsupervised dose escalation.
Can a normal testosterone result rule out all causes of hirsutism?
No. Assay quality, timing, medicines and phenotype matter. The Endocrine Society recommends reliable free-testosterone assessment when total testosterone is normal but hirsutism is moderate or severe, progressing, or associated with other hyperandrogenic features. Targeted tests and imaging are selected from the history and examination, not ordered indiscriminately.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic